Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The company operates one of the world's largest libraries of multimodal clinical and molecular data, providing an operating system to make that data accessible and useful for healthcare providers. Tempus offers genomic testing, molecular diagnostics, and AI-powered clinical decision support across oncology, cardiology, radiology, and mental health applications.
Tempus Health is publicly traded
IPO'd on Jun 14, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under TEM.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Employees
2,300–2,500
Total Funding
$1.12B
11 rounds
Last Private Valuation
$8.1B
Dec 10, 2020
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $1.12B across 11 rounds
Last updated 06-25-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Apr 2024 | Series G-5 | $200M | — | SoftBank Group |
| Oct 11, 2023 | Series G-4 | $45M | — | Not disclosed |
| Apr 2022 | Series G-3 | $92.5M | — | Not disclosed |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Entry · Series E
$2B
Aug 2018
Tempus Health today
$8.1B
Dec 2020 · latest mark
Tempus Health multiple
4.0x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Eric Lefkofsky
Founder and CEO
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Exact Sciences
Precision medicine company developing clinically validated genomic and molecular tests for early cancer detection, screening, and monitoring.
Guardant Health
Molecular diagnostics company providing genomic sequencing and precision oncology testing services.
Foundation Medicine
Genomic testing company for solid tumors and hematologic cancers (acquired by Roche in 2018).
Caris Life Sciences
Precision oncology diagnostics company offering tumor profiling and molecular testing services.
Neogenomics
Laboratory and genomics company providing cancer diagnostics and oncology testing services.
Yes, Tempus Health is publicly traded under the ticker symbol TEM on the NASDAQ. The company went public in Jun 14, 2024.
Tempus Health trades under the ticker symbol TEM on the NASDAQ. It began trading in Jun 14, 2024.
Tempus Health (TEM on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker TEM to place an order.
Tempus Health went public in Jun 14, 2024 via ipo, with an offering valuation of approximately $8.1B. Tempus AI completed its initial public offering on June 14, 2024, pricing 11.1 million shares at $37.00 per share on the Nasdaq Global Select Market under ticker symbol TEM. The IPO raised $410.7 million in gross proceeds at an implied valuation of approximately $6.1 billion.
Tempus Health raised $1.12B across 11 disclosed funding rounds prior to its public listing.
Tempus Health was founded by Eric Lefkofsky in 2015.
Tempus Health is headquartered in Chicago, Illinois, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.